Role of ferric carboxymaltose in battle with anemia among north Indian pregnant women
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20233304Keywords:
Ferric carboxymaltose, Iron deficiency anemia, Iron sucrose, Mean cell haemoglobin, Mean cell hemoglobin concentration, Mean cell volume, Total iron binding capacityAbstract
Background: Anemia among pregnant women is a serious global health concern. Anemia is a major hematological, nutritional deficiency but still a manageable health problem among the pregnant women and very common in developing countries like India in under privileged population. Increased morbidity and mortality is seen in pregnant women and their foetuses suffering from anemia. Aim of this study was to study safety and efficacy of injection ferric carboxymaltose in pregnant women with iron deficiency anemia.
Methods: This is a Prospective interventional comparative randomized study carried among antenatal women in the Department of Obstetrics and Gynaecology, S. N. Medical College, Agra from (May 2021-October 2022), comprised of 200 pregnant women divided into two groups. Group A-100 antenatal women were transfused with iron sucrose (IS), Group B-100 antenatal women were transfused with ferric carboxymaltose (FCM).
Results: In FCM group after 3 weeks of post transfusion hemoglobin level was 10.5±0.44 and in iron sucrose group it was 9.9±0.59 (p=0.0001). 6 week post transfusion hemoglobin level in FCM group was 11.37±0.62 and in iron sucrose group it was 10.45±0.59 (p=0.0001). Average rise in hemoglobin in FCM group after 3 week post transfusion was 2.9±0.02 and after 6 week it was 3.77±0.16. In iron sucrose group at 3 week it was 2.1±0.06 and at 6 week it was 2.65±0.04. The average rise in hemoglobin level was greater among patients of FCM compared to Iron sucrose group.
Conclusions: Ferric carboxymaltose was safe and more effective in treatment of iron deficiency anaemia in pregnant women as compared to iron sucrose with lesser side effect and better patient compliance.
References
World Health Organization. Vitamin and Mineral Nutrition Information System (VMNIS) Worldwide prevalence on anaemia 1993-2005 Summary of the worldwide prevalence on anaemia. Available at: https://www.who.int/vmnis/database/ anaemia/anaemia_status_summary/en/. Accessed 24 December, 2020.
National Family Health Survey Key findings from NFHS-5. Available at: http://rchiips.org/nfhs/factsheet_NFHS-5.shtml. Accessed 24 December, 2020.
World Health Organization. Micronutrient deficiencies: prevention and control guidelines. Geneva: World Health Organization, 2015. Available at: https://www.who.int/nutrition/publications/ WHO_WFP_UNICEFstatement.pdf. Accessed on 10th February 2020.
FOGSI General Clinical Practice Recommendations. Management of iron deficiency anaemia in pregnancy, 2016. Available at: http://www.fogsi.org/wpcontent/uploads/2016/ 05/The-evidence-base_IDAPregnancy-24-May-2016-Clean.pdf. Accessed 12th February 2020.
Helmy ME, Elkhouly NI, Ghalab RA. Maternal anemia with pregnancy and its adverse effects. Menoufia Med J. 2018;31(1):7-11.
Smith C, Teng F, Branch E, Chu S, Joseph KS. Maternal and perinatal morbidity and mortality associated with anemia in pregnancy. Obstetrics and Gynecol. 2019;134(6):1234-44.
WHO. The Global Prevalence of anemia in 2011, 2015. Available at: https://www.who.int/publications/i/item/9789241564960. Accessed on 30th September 2015.
WHO. Comparative quantification of health risks. Available at: http://www.who.int/healthinfo/global_burde_ disease/cra/en/. Accessed 12 November 2017.
Centre for disease control. Criteria for anaemia in children and child bearing age women. MMWR. 1989;38:400-4. Available at; https://www.cdc.gov/MMWR/preview/mmwrhtml/0005 1880.htm. Accessed 15th November 2018.
FOGSI General Clinical Practice Recommendations. Management of iron deficiency anemia in pregnancy. Available at: www.fogsi.org/wp-content/uploads/2017/07/gcpr-recommendation-ida.pdf. Accessed on 24th December 2020.
Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anemia during pregnancy and postpartum. Arch Gynecol Obstet. 2010;282(5):577-80.
Tandon R, Jain A, Malhotra P. Management of iron deficiency anemia in pregnancy in India. Indian J Hematol Blood Transfus. 2018;34(2):204-15.
Auerbach M. Commentary: iron deficiency of pregnancy–a new approach involving intravenous iron. Reprod Health. 2018;15(Suppl 1):96.
Chauhan A, Prasad M. Outcome of pregnancy with hemoglobinopathy in a tertiary care center. J Obstet Gynaecol India. 2018;68(5):394-9.
Khatun F, Biswas C. Comparative study of intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy. Int J Reprod Contracept Obstet Gynecol. 2022;11(2):505-12.
VanWyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anaemia: a randomized controlled trial. Obstet Gynecol. 2007;110(2 Part 1):267-78.
Kumari S, Singh SHK. Iron sucrose or ferric carboxy maltose: comparative study for treatment of postpartum iron deficiency anemia. Int J Med Res Prof. 2019;5(1):157-62.
Verma U, Singh S, Chandra M, Chandra M, Garg R, Singh S, et al. To evaluate the efficacy and safety of single dose intravenous iron carboxymaltose verses multidose iron sucrose in postpartum cases of severe iron deficiency anemia. Int J Reprod Contracept Obstet Gynecol. 2015;4(2):442-6.
Mahapatra PC, Gupte S, Gopinath PM, Pandit SN, Tandulwadkar S, Gupta M, et al. Ferric Carboxymaltose for the Treatment of Anemia during Antenatal and Postpartum Period: Expert Opinion. J South Asian Feder Obst Gynae. 2022;14(3):292-301.
